Annual General Meeting of Q-Med AB (publ)

The Annual General Meeting of Q-Med AB (publ) (STO:QMED) was held on April 29, 2008 at 3 p.m.

Dividend The meeting decided that a dividend of 1.50 SEK per share shall be paid to shareholders.

Board and fees The meeting decided to re-elect the following members of the Board: Hakan Edstrom, Bertil Hult, Anders Milton, Pia Rudengren, Asa Roden, Pernilla Strom och Bengt Agerup for the period up until the end of the next Annual General Meeting. The meeting also re-elected Pia Rudengren as the Chair of the Board.

The meeting also decided that Board fees of 1,400,000 (1,050,000) SEK in total be paid for the period 2007/2008, with 400,000 (300,000) SEK to the Chair of the Board and 200,000 (150,000) SEK to each of the other members of the Board, except for Bengt Agerup, who is an employee of the company and shall therefore not receive a Board fee.

Auditors' fees shall be paid in accordance with reasonable invoicing.

A fee of 200,000 (180,000) SEK in total shall be paid for work on the audit committee, to be divided among the three members as follows: 100,000 (90,000) SEK to the Chair of the committee and 50,000 (45,000) SEK to each of the other two committee members.

Election committee The majority of the election committee proposed that the election committee shall continue to consist of three members, with Robert Wikholm as Chair with the assignment of finding, at the latest during the third quarter, two representatives to be included in the election committee, but with the difference from previous years that one representative is to come from the major owners and one is to represent the smaller shareholders. Furthermore, it was proposed that a fee of SEK 75,000 (60,000) be paid to the election committee, to be allocated in accordance with the decision of the election committee.

The minority of the election committee, Jan-Erik Erenius, who represents AMF Pension, proposed an alternative procedure, which was supported by a number of institutional owners. The Swedish Shareholders' Association proposed a third alternative, according to which the election committee in its entirety would be elected by the Annual General Meeting. A majority of the Annual General Meeting decided in accordance with the proposal of the majority.

Principles for remuneration Finally, the meeting decided on principles for remuneration and other conditions of employment for senior management in accordance with the proposal of the Board.

Queries should be addressed to:

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane(R) for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux(R) for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta(TM) for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

This information was brought to you by Cision http://newsroom.cision.com